Publication:
Existing and investigational medications for refractory chronic spontaneous urticaria: safety, adverse effects, and monitoring

Placeholder

Organizational Units

Program

KU Authors

Co-Authors

Saini, Sarbjit S.
Rubeiz, Christine J.
Bernstein, Jonathan A.

Advisor

Publication Date

2022

Language

English

Type

Review

Journal Title

Journal ISSN

Volume Title

Abstract

Treatment of chronic spontaneous urticaria (CSU) is responsive to H1 antihistamines administered up to four times the recommended US Food and Drug Administration dose in approximately 50% of patients. However, when patients do not respond to these first-line agents, evidence-based guidelines using Grading of Recommendations, Assessment, Development, and Evaluations methodology have provided direction for second-and third-line treatments that can effectively treat patients with CSU. Some patients remain refractory to these advanced treatments; therefore, alternative treatments with a lower certainty of evidence may be necessary. Regardless of the therapies used to treat CSU patients, it is essential for clinicians to be knowledgeable about the mechanism of action, efficacy, and safety and monitoring recommendations of the treatments prescribed. This review provides a comprehensive review of the adverse effects and monitoring recommendations for agents in use for CSU treatment as well as those currently undergoing investigation for CSU treatment.

Description

Source:

Journal of Allergy and Clinical Immunology-in Practice

Publisher:

Elsevier

Keywords:

Subject

Allergy, Immunology

Citation

Endorsement

Review

Supplemented By

Referenced By

Copy Rights Note

0

Views

0

Downloads

View PlumX Details